#10/43
Harry
Jun 30 01

MEWB25.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|---|---|---|---|
| Applicant | : | Lane, David Philip | Group Art Unit 1642 |
| Appl. No. | : | 09/403,440 | |
| Filed | : | January 19, 2000 | |
| For | : | MATERIALS AND METHODS RELATING TO INHIBITING THE INTERACTION OF p53 AND MDM2 | |
| Examiner | : | Davis, M. | |

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

June 11, 2001
(Date)

Ginger R. Dreger, Reg. No. 33,055

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed on March 30, 2001 (Paper No. 7) kindly amend this application as follows:

In the Specification:

Please insert the attached Sequence Listing into the specification, immediately following the claims.

Please replace the paragraph starting at page 2, line 12 with the following new paragraph:

-- WO 96/02642 describes experiments to refine the peptide motif of p53 responsible for binding to mdm2, and shows that the motif is less extensive than disclosed in WO 93/20238. WO 96/02642 discloses that a FXaaXaaLW (SEQ ID NO: 1) motif between amino acid residues 18-23 of p53 (where Xaa is any amino acid) is sufficient to bind to mdm2. This motif can be used to screen for therapeutic compounds capable of disrupting the interaction so that the transcriptional activity of p53 in cells overexpressing mdm2 can be restored. --

93
1